NACDS Statement on FDA's Recommendation to Reschedule Hydrocodone

OCTOBER 25, 2013
PRESS RELEASE

Arlington, Va. - NACDS issued the following statement on October 24 regarding news that the Food and Drug Administration (FDA) is recommending the rescheduling of combination hydrocodone medications from Schedule III to Schedule II:

“Pharmacies have a zero tolerance for prescription drug abuse and a 100-percent commitment to patient care. This proposal is not the best avenue to address abuse, and would negatively impact access to needed medications for those who suffer from chronic pain. In the interest of patient care, we have worked with patient advocacy groups in opposition to this recommendation as we support and advance workable solutions.”

For more information, please see a recent column by NACDS President and CEO Steven C. Anderson, IOM, CAE, titled “Addressing Prescription Drug Abuse and Access Issues – Every Day.”

SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.